Welcome to our dedicated page for Citius Pharmaceuticals SEC filings (Ticker: CTXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nevada-incorporated biopharmaceutical issuer (Commission File Number 001-38174), Citius Pharmaceuticals reports material events, financing transactions, and other corporate developments through forms such as Form 8-K and registration statements on Form S-3.
In its recent Form 8-K filings, Citius Pharmaceuticals has described securities purchase agreements for registered direct offerings of common stock, pre-funded warrants and common warrants, including details on exercise prices, terms, placement agent arrangements and intended use of proceeds. The company states that net proceeds are expected to support the commercial launch of LYMPHIR, milestone and regulatory payments, development initiatives for its product candidates, and general corporate purposes.
Other 8-K filings referenced by the company include notices of compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement, as well as disclosures about corporate presentations and earnings press releases furnished under Regulation FD and Item 2.02. Together, these filings offer insight into CTXR’s capital strategy, listing status and communication practices with investors.
Through Stock Titan, users can review CTXR’s current and historical SEC documents, including registration statements that underpin shelf offerings and the associated prospectus supplements. The platform pairs these filings with AI-powered summaries designed to clarify key terms, highlight significant financing structures, and explain how reported events relate to the company’s commercialization of LYMPHIR and its late-stage pipeline assets Mino-Lok and CITI-002 (Halo-Lido). This makes it easier to understand complex documents such as 8-Ks, S-3 registration statements, and related exhibits without reading every line of legal text.
Citius Pharmaceuticals, through its majority-owned subsidiary Citius Oncology, reported positive topline results from an investigator-initiated Phase 1 study of LYMPHIR™ (denileukin diftitox-cxdl) plus pembrolizumab in patients with recurrent or refractory gynecologic cancers.
The study in 25 evaluable patients showed no unexpected safety signals or serious immune-related adverse events at any dose level. Among 21 efficacy-evaluable patients, investigators observed a 24% objective response rate and a 48% clinical benefit rate, defined as complete or partial response or stable disease for at least six months.
The trial aimed to identify a recommended Phase 2 dose, and full safety and efficacy data are planned for presentation at an international cancer conference. LYMPHIR is already FDA‑approved and launched for relapsed or refractory Stage I–III cutaneous T‑cell lymphoma, where management estimates the initial market currently exceeds $400 million.
Citius Pharmaceuticals, through majority-owned subsidiary Citius Oncology, reported positive preliminary Phase 1 data for LYMPHIR when given before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma. In 14 treated patients, investigators observed an 86% overall response rate, including 57% complete and 29% partial responses, with LYMPHIR described as well tolerated and without dose-limiting toxicities. The study was designed to enhance CAR-T effectiveness by depleting regulatory T-cells, and full results were presented at the 2026 Tandem Meetings. The attached exhibit also reiterates LYMPHIR’s existing FDA approval for cutaneous T-cell lymphoma and includes detailed safety warnings, highlighted by a boxed warning for capillary leak syndrome and other serious risks.
Citius Pharmaceuticals is asking stockholders to vote at its April 6, 2026 annual meeting on electing seven directors for one-year terms and ratifying Wolf & Company, P.C. as auditor for the fiscal year ending September 30, 2026.
Stockholders of record as of February 13, 2026, when 22,376,427 common shares were outstanding, are entitled to one vote per share. A majority of votes represented and entitled to vote is required to elect directors and ratify the auditor. The board reports that five of seven director nominees are independent under Nasdaq rules and highlights its committee structure, executive and director pay practices, and employment and severance arrangements for senior management.
Citius Pharmaceuticals’ major shareholder updates its ownership. CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. report beneficial ownership of 2,394,725 shares of Citius common stock, representing 9.9% of the outstanding shares as of December 31, 2025.
The position includes 799,934 common shares plus additional shares issuable from warrants, which are subject to 4.99% and 9.99% beneficial ownership limits. The reporting parties state the securities are not held for the purpose of changing or influencing control of Citius.
Citius Pharmaceuticals reported its first product revenue after the December 2025 launch of LYMPHIR through majority-owned Citius Oncology, recording $3.9 million in revenue for the fiscal first quarter ended December 31, 2025. Total revenue was $3,944,111, with a net loss attributable to common stockholders of $8,220,785, or $0.38 per share.
Cash and cash equivalents were $7,721,393 as of December 31, 2025, supported by $20,877,925 in net proceeds from common stock offerings during the quarter. Net cash used in operating activities was $13,008,822, and the company also paid $4,400,000 in license fees.
Citius received a Nasdaq notice that its common stock bid price has stayed below the $1.00 minimum for 30 consecutive business days. The company has 180 days, until August 10, 2026, to regain compliance, with the possibility of an additional 180-day period, and is evaluating options including a potential reverse stock split. The notice has no immediate effect on the Nasdaq Capital Market listing.
Citius Pharmaceuticals reported its first commercial revenue from LYMPHIR in the quarter ended December 31, 2025, generating
Management states that existing cash is expected to fund operations only through May 2026 and that there is “substantial doubt” about the ability to continue as a going concern without additional capital. Citius also received a Nasdaq notice in February 2026 for failing to meet the
Citius Pharmaceuticals filed an amended annual report to update the non‑financial Part III sections for the year ended September 30, 2025. The amendment adds detailed information on directors and executive officers, compensation, equity plans, related‑party transactions and auditor fees, but does not change previously reported financial results.
The filing describes the current board and management team, their roles and committee assignments, and confirms most directors meet Nasdaq independence standards. It outlines executive pay structures, including salaries, target bonuses and stock‑based incentives, and summarizes employment and severance terms for key executives.
The report shows equity compensation activity and that 839,510 shares are subject to outstanding awards, with 118,000 shares remaining available under the 2023 plan. It discloses insider ownership levels, related‑party warrant term extensions involving senior executives, and audit, audit‑related and tax fees paid to the independent auditor, all of which were pre‑approved by the Audit and Risk Committee.
Citius Pharmaceuticals reported that it posted an updated Corporate Presentation on its website and furnished it as Exhibit 99.1 in an Item 7.01 Regulation FD disclosure. The company noted that this information is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference unless specifically referenced in a future filing.
Citius Pharmaceuticals (CTXR) completed a registered direct offering with an institutional investor, issuing 1,460,000 common shares at $1.51 and pre-funded warrants for up to 2,513,510 shares at $1.5099. The company also issued investor warrants to purchase up to 3,973,510 shares at an exercise price of $1.40, exercisable immediately for five years.
Gross proceeds were approximately $6.0 million, with expected net proceeds of about $5.5 million after fees. Citius plans to use the funds to support the commercial launch of LYMPHIR™, milestone and regulatory payments, development initiatives across its pipeline, and general corporate purposes. H.C. Wainwright acted as placement agent, earning a 7.0% cash fee plus expenses and received placement agent warrants for up to 278,146 shares at a $1.8875 exercise price.
The warrants include a 4.99% (or 9.99% if elected) Beneficial Ownership Limitation and allow cashless exercise if no effective resale registration is available. For 90 days after closing, Citius agreed not to issue additional equity, with an exception permitting “at the market” sales after 30 days at $2.15 or higher.